Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Neurogenetics Laboratory - |
RCV000417018 | SCV000494562 | uncertain significance | Epileptic encephalopathy | 2016-11-16 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000556057 | SCV000632038 | uncertain significance | Idiopathic generalized epilepsy | 2017-06-08 | criteria provided, single submitter | clinical testing | In summary, this variant has uncertain impact on GABRD function. The available evidence is currently insufficient to determine its role in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with a GABRD-related disease. ClinVar contains an entry for this variant (Variation ID: 375540). This variant is not present in population databases (ExAC no frequency). This sequence change replaces valine with isoleucine at codon 370 of the GABRD protein (p.Val370Ile). The valine residue is moderately conserved and there is a small physicochemical difference between valine and isoleucine. |